Riess JW, Frankel P, Shackelford D, Dunphy M, et al. Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design. Clin Lung Cancer 2021;22:67-70.
PMID: 33229301